- CureToday.com
- OncLive.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Michael J. Morris, MD | Authors
Articles
Michael J. Morris, MD, on Future Directions of PSMA Imaging in Prostate Cancer
July 03, 2020
Results of phase 3 CONDOR study could have a far-reaching impact on patients with prostate cancer.
Michael J. Morris, MD on the Impact of PyL-PET/CT Scans on the Clinical Management of Patients With Prostate Cancer
June 04, 2020
An analysis of the secondary endpoint of the phase III CONDOR study showed PSMA scans had a profound impact on patient care.
CHAARTED: ADT Plus Docetaxel in Prostate Cancer
June 30, 2014
Dr. Morris discusses results and implications of the CHAARTED trial, which studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.